Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.72 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.72 |
| ▸ | AR | P10275 | 4/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.48 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.48 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.48 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.48 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.48 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.48 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.48 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14555723 | 0.96 | CYP11B1 (0.68) | CYP11B1CYP11B2ARTRPV4TUBB4A | |
| SCHEMBL14555682 | 0.90 | CYP11B2 (0.65) | CYP11B1CYP11B2ARTRPV4TUBB4A | |
| SCHEMBL20460002 | 0.85 | CYP11B2 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL4000273 | 0.84 | CYP11B2 (0.64) | CYP11B1CYP11B2ARTRPV4PTPRC | |
| SCHEMBL24084158 | 0.83 | CYP11B2 (0.54) | CYP11B1CYP11B2ARTRPV4 | |
| SCHEMBL18297999 | 0.82 | CYP11B2 (0.67) | CYP11B1CYP11B2TRPV4 | |
| SCHEMBL16581280 | 0.82 | CYP11B2 (0.70) | CYP11B1CYP11B2ARTUBB4ATUBB | |
| SCHEMBL30132416 | 0.81 | CYP11B1 (0.78) | CYP11B1CYP11B2TRPV4 | |
| SCHEMBL1514257 | 0.81 | CYP11B1 (0.78) | CYP11B1CYP11B2TRPV4 | |
| SCHEMBL2947210 | 0.80 | CYP11B1 (0.51) | CYP11B1CYP11B2ARTUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170357131-A1 | LIGHT MODULATION ELEMENT | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
| US-20170342324-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-11-30 | — | — | US | disclosed |
| US-20170327741-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
| US-9758727-B2 | Bimesogenic compounds and mesogenic media | MERCK PATENT GMBH (DE) | 2017-09-12 | — | — | US | disclosed |
| US-9752075-B2 | Mesogenic media and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-20170210990-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170190971-A1 | MESOGENIC MEDIA AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2017-07-06 | — | — | US | disclosed |
| US-9644144-B2 | Bimesogenic compounds and mesogenic media | MERCK PATENT GMBH (DE) | 2017-05-09 | — | — | US | disclosed |
| US-20170002268-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| US-20160298031-A1 | MESOGENIC MEDIA AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| EP-2166003-A1 | Excitatory amino acid receptor antagonists | Eli Lilly & Company (US) | 2010-03-24 | — | — | EP | disclosed |
| EP-2166003-A1 | Excitatory amino acid receptor antagonists | Eli Lilly & Company (US) | 2010-03-24 | — | — | EP | disclosed |
| US-7601738-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601738-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601738-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7205313-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205313-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205313-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | ARNOLD MACKLIN B | 2006-05-11 | — | — | US | disclosed |
| US-20040138254-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138254-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, GRIN1 | CYP11B1 2448/4885CYP11B2 2355/4885AR 1391/4885 |
| US-20170327741-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | CYP11B1 1497/4885CYP11B2 1424/4885AR 4187/4885 |
| US-20170210990-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | CYP11B1 1497/4885CYP11B2 1424/4885AR 4187/4885 |
| US-20170342324-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MTX1, S100A11, MCRS1 | CYP11B1 463/4885CYP11B2 707/4885AR 3840/4885 |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, GRIN1 | CYP11B1 2448/4885CYP11B2 2355/4885AR 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.